West Pharmaceutical Services (WST) Return on Capital Employed (2010 - 2026)

West Pharmaceutical Services (WST) has reported Return on Capital Employed for 17 consecutive years, with 19.71% the latest figure, recorded in Q2 2026.

• Quarterly Return on Capital Employed rose 142.0% year-over-year to 19.71% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 19.71% (up 142.0% YoY) and the FY2025 annual result came in at 17.71%, down 17.0% from the prior year.
• Return on Capital Employed rose to 19.71% in Q2 2026 per WST's latest filing, from 18.63% in the prior quarter.
• Over the last five years, Return on Capital Employed for WST reached as high as 28.36% in Q2 2022 and fell as low as 16.56% in Q4 2025.
• A 5-year average of 21.11% and a median of 20.22% in 2023 frame the typical range for Return on Capital Employed.
• Annual changes were most pronounced in 2022 — Return on Capital Employed soared 653 bps — and 2023, when it sank 783 bps.
• Year by year, Return on Capital Employed stood at 24.9% in 2022, then declined by 13 bps to 21.66% in 2023, then fell by 15 bps to 18.33% in 2024, then retreated by 10 bps to 16.56% in 2025, then rose by 19 bps to 19.71% in 2026.
• According to Business Quant data, Return on Capital Employed over the past three periods registered 19.71%, 18.63%, and 16.56% for Q2 2026, Q1 2026, and Q4 2025 respectively.